^
    1d
    MP0533-CP101: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=249, Active, not recruiting, Molecular Partners AG | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2027 | Trial primary completion date: Dec 2027 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Venclexta (venetoclax) • azacitidine • Gazyva (obinutuzumab) • MP0533
    1d
    PEPN1812: Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Dec 2026
    Trial completion date
    |
    cytarabine • flotetuzumab (MGD006) • Starasid (cytarabine ocfosfate)
    6d
    Shared Care Offers an Effective Framework for Managing Tagraxofusp Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm. (PubMed, Acta Haematol)
    Key Messages: Shared care is particularly suitable for tagraxofusp treatment, as adverse events can be grade 3 or greater, but typically only occur in cycle 1, if they are to occur at all. Based on clinical experience, this article discusses the application of a shared-care model for tagraxofusp treatment in BPDCN.
    Review • Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Elzonris (tagraxofusp-erzs)
    19d
    NCI-2022-02215: A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure (clinicaltrials.gov)
    P2, N=51, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2026 --> May 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date • Minimal residual disease
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    vibecotamab (XmAb14045)
    1m
    Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Kansas Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elzonris (tagraxofusp-erzs) • Vonjo (pacritinib)
    2ms
    Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, Tang-Du Hospital
    New P1/2 trial
    |
    vibecotamab (XmAb14045)
    2ms
    TAGALONG: Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents (clinicaltrials.gov)
    P2, N=53, Recruiting, Joshua Zeidner | Trial completion date: Dec 2027 --> Jul 2031 | Trial primary completion date: Aug 2027 --> Jul 2030
    Trial completion date • Trial primary completion date
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)
    3ms
    Efficacy and Safety of SBRT Combined With Becotatug Vedotin in EGFR-Positive Metastatic Tumor Patients With Oligometastases (clinicaltrials.gov)
    P3, N=200, Not yet recruiting, Ming-Yuan Chen
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin) • becotarug (JMT101) • vibecotamab (XmAb14045)
    4ms
    A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax (clinicaltrials.gov)
    P1/2, N=31, Recruiting, Jacqueline Garcia, MD | Trial completion date: Dec 2028 --> Dec 2030 | Trial primary completion date: Dec 2026 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Venclexta (venetoclax) • Elzonris (tagraxofusp-erzs)
    4ms
    Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies (clinicaltrials.gov)
    P1, N=13, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Aug 2025 | Trial primary completion date: May 2026 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    flotetuzumab (MGD006)
    5ms
    PEPN1812: Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Mar 2026
    Trial completion date
    |
    cytarabine • flotetuzumab (MGD006) • Starasid (cytarabine ocfosfate)
    5ms
    Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P1/2, N=64, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    decitabine • Elzonris (tagraxofusp-erzs)